IntrinsicIntrinsic
← All summaries

Zoetis Inc.

ZTS
Financials & Chart →

Business Summary

Zoetis Inc. operates as a global leader in the animal health industry, focusing on the discovery, development, manufacture, and commercialization of a diverse portfolio of products including medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health. The company's business is diversified across eight core species: dogs, cats, and horses (companion animals), and cattle, swine, poultry, fish, and sheep (livestock), and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. Zoetis was incorporated in Delaware in July 2012, having previously been a business unit of Pfizer Inc. The animal health industry is characterized by meaningful differences in customer needs across regions due to economic, cultural, epidemiological, treatment, environmental, and regulatory factors.

The company's core business model involves generating revenue primarily from its diversified product portfolio for companion animal and livestock customers. Revenue is derived from product sales, which are promoted to veterinarians and livestock producers by a sales organization comprising sales representatives and technical and veterinary operations specialists. Products are then sold directly by Zoetis or through distributors, retailers, or e-commerce outlets. Companion animal products represented approximately 70% of total revenue for the year ended December 31, 2025 , while livestock products accounted for approximately 29% of total revenue for the same period . Contract manufacturing services to third parties and human health diagnostics products contributed approximately 1% of total revenue .

Zoetis organizes and operates its business in two segments: United States (U.S.) and International. The U.S. segment generated revenue of $5,097 million for the year ended December 31, 2025, representing 54% of total revenue . Within the U.S. segment, companion animal products accounted for 83% of revenue, and livestock products for 17% . The International segment reported revenue of $4,254 million , or 45% of total revenue , with companion animal products contributing 56% and livestock products 44% . The company directly markets its products in approximately 45 countries and sells them in over 100 countries.

The company's major product categories include parasiticides, which generated $2,341 million in revenue in 2025; vaccines, with $1,959 million ; dermatology, contributing $1,754 million ; anti-infectives, at $1,036 million ; pain and sedation, with $840 million ; other pharmaceuticals, at $697 million ; and animal health diagnostics, generating $434 million . Other non-pharmaceuticals contributed $263 million . The medicated feed additive product portfolio was divested on October 31, 2024 . In 2025, the two top-selling product lines, Simparica/Simparica Trio and Apoquel/Apoquel Chewable, contributed approximately 16% and 12% of total revenue, respectively. Combined with Cytopoint, Librela, and the ceftiofur line, these five product lines accounted for approximately 42% of revenue . The ten top-selling product lines contributed approximately 57% of total revenue .

For the fiscal year ended December 31, 2025, total revenue was $9,467 million , an increase of 2% from $9,256 million in 2024. Gross profit, calculated as revenue less cost of sales, was $6,801 million in 2025, compared to $6,537 million in 2024. The gross margin was 71.8% in 2025, an improvement from 70.6% in 2024. Operating income, defined as income before provision for taxes on income, was $3,360 million in 2025, up from $3,133 million in 2024, resulting in an operating margin of 35.5% in 2025 compared to 33.8% in 2024. Net income attributable to Zoetis Inc. was $2,673 million in 2025, an 8% increase from $2,486 million in 2024. Diluted EPS was $6.02 in 2025, up from $5.47 in 2024. Net cash provided by operating activities was $2,904 million in 2025. Cash and cash equivalents stood at $2,312 million as of December 31, 2025, while total long-term debt, net of discount and issuance costs, was $9,042 million .

Year-over-year, total revenue increased by $211 million , or 2% , in 2025 compared to 2024, reflecting operational revenue growth of $247 million , or 3% . This growth was primarily driven by price increases of approximately 4% and volume growth from other in-line products of approximately 1% , and key franchises of approximately 1% . This was partially offset by a volume decrease of approximately 3% due to the MFA divestiture. Foreign exchange unfavorably impacted reported revenue growth by approximately $36 million , or 1% . U.S. segment revenue was relatively flat, increasing by $23 million , with companion animal revenue growing by $166 million and livestock revenue declining by $143 million . International segment revenue increased by $152 million , or 4% , with operational growth of $188 million , or 5% , driven by companion animal products ($145 million ) and livestock products ($43 million ).

Significant operational developments during the period include the acquisition of Veterinary Pathology Group, a veterinary diagnostic laboratory group in the U.K. and Ireland, in 2025 . In 2023, Zoetis acquired PetMedix Ltd and adivo GmbH, both research and development stage animal health biopharmaceutical companies focused on antibody-based therapeutics for companion animals . The company also enhanced its Vetscan Imagyst platform by adding artificial intelligence (AI) dermatology and AI fecal for equine in 2023, and AI urine sediment analysis and Vetscan OptiCell in 2024, followed by AI Masses in 2025 . On October 31, 2024, Zoetis completed the divestiture of its medicated feed additive product portfolio, certain water soluble products, and related assets .

Business Outlook

Zoetis expects to eliminate the one-month lag in reporting for its subsidiaries operating outside the U.S. in 2026, aligning the fiscal years of all subsidiaries to December 31 . This Expected Fiscal Year Alignment is a preliminary step in the transition of the company's enterprise resource planning (ERP) system and is anticipated to contribute to more seamless financial consolidation, regulatory compliance, and consistent reporting . As a result of this alignment, the International segment's revenue in the reported fourth quarter of 2025 benefited from operational changes that accelerated the timing of sales, leading to an approximate 2.5% to 3.5% increase in sales , a trend not expected to recur at the end of fiscal year 2026 .

The company's growth strategy is centered on leading through innovation across its diverse portfolio, delivering an exceptional customer experience, powering its business through digital solutions and data insights, supporting a thriving workplace for colleagues, advancing sustainability, and performing with excellence and agility . Zoetis is focused on innovating across vaccines, pharmaceuticals, diagnostics, genetics, biodevices, and other product segments for all core species, leveraging both internal R&D capabilities and external collaborations . The company's R&D efforts are comprised of more than 300 programs , with a significant share of investment focused on product lifecycle innovation, such as developing new claims, extending to additional species, and creating more convenient formulations .

Operationally, Zoetis intends to continue its efficiency improvement programs in its manufacturing and supply chain organization, including Six Sigma and Lean capabilities . The company is expanding manufacturing capabilities at certain existing sites and purchased a new manufacturing site outside Atlanta, Georgia, in 2023, with commercial production planned for the future . The ongoing multi-year implementation of a new fully cloud-based ERP system is a major global and cross-functional effort expected to transform business operations and contribute to strategic priorities .

In terms of capital allocation, Zoetis incurred R&D expenses of $698 million in 2025 and plans to continue strategic investments in R&D based on strategic fit, technical feasibility, return on investment, and customer needs . The Board of Directors authorized a multi-year share repurchase program of up to $6 billion in August 2024, with $2.4 billion remaining under this authorization as of December 31, 2025. The company's quarterly cash dividend was $0.50 per share of common stock in fiscal year 2025 , and it expects to continue paying dividends consistent with historic payments . Zoetis also expects to contribute a total of $8 million to its international defined benefit pension plans in 2026.

Management has flagged several structural headwinds and execution risks. The animal health industry is highly competitive, with principal drivers including new product development, quality, price, service, and promotion . The company faces competition from standalone animal health businesses, start-ups, and animal health divisions of large pharmaceutical companies, some of which may have greater resources . Increased consolidation in the animal health industry could lead to competitors gaining efficiencies or improving portfolio bundling, potentially increasing their market share and pricing power . Zoetis also faces competition from lower-priced generic alternatives, which have negatively affected sales of products like Draxxin, which declined by 66% in the U.S. since 2021 . Consolidation of customers and distributors could lead to demands for more favorable pricing, impacting margins . Changes in distribution channels for companion animal products, such as increased reliance on internet-based retailers and "big-box" stores, could reduce market share and margins .

Geographic, regulatory, and macro factors also pose constraints. International operations are subject to risks such as currency fluctuations, capital and exchange control regulations, expropriation, and other restrictive government actions . Macroeconomic, business, political, and financial disruptions, including public health crises, ongoing conflicts, economic weakness in China, and inflation, could adversely affect operating results, financial condition, and liquidity . Restrictions and bans on the use of antibacterials in food-producing animals, driven by concerns over antibacterial resistance, could negatively impact sales of the company's antibacterial products for livestock, which generated approximately $713 million in revenue in 2025 . Increased regulation or decreased governmental financial support for the livestock industry could reduce demand for products . Changes in trade policies, including tariffs, sanctions, and other restrictions, may raise costs, disrupt supply chains, and reduce demand . Adverse weather conditions, natural disasters, and climate change could impact manufacturing, supply chains, and customer operations, particularly in the livestock industry .

Risk Factors

Zoetis faces material risks from global macroeconomic and geopolitical conditions, including ongoing conflicts, rising tensions, economic weakness in China, and inflation, which could adversely affect operating results, financial condition, and liquidity. The animal health industry is highly competitive, with competition from standalone businesses, start-ups, and large pharmaceutical companies, some possessing greater resources. Consolidation in the industry could intensify competition and impact pricing power. The company is exposed to generic competition, with sales of Draxxin, for example, declining by 66% in the U.S. since 2021 due to generic alternatives. Regulatory risks are substantial, with operations subject to diverse and evolving laws in numerous jurisdictions, including those governing product approval, manufacturing, data protection, and environmental health and safety. Non-compliance or delays in approvals could lead to fines, production shutdowns, product recalls, or market withdrawals. Changes in trade policies, such as tariffs and sanctions, may increase costs and disrupt supply chains. The company's total revenue from antibacterials for livestock was approximately $713 million in 2025 , making it vulnerable to restrictions or bans on antibacterial use in food-producing animals due to resistance concerns. Furthermore, the company's reliance on complex information technology systems and increasing use of AI expose it to cyberattacks, ransomware, and data breaches, which could result in significant financial and legal exposure, as well as reputational damage.

Management Priorities

Management's message to shareholders emphasizes Zoetis's vision to be the most trusted and valued animal health company, shaping the future of animal care through innovation, customer obsession, and purpose-driven colleagues. The company is committed to pioneering ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, pet owners, and livestock producers worldwide. Management explicitly states that in 2026, the company expects to eliminate the one-month lag in reporting for its subsidiaries operating outside the U.S. and align the fiscal years of all subsidiaries to December 31 . This alignment is a key preliminary step in the multi-year transition of the company's ERP system, which is expected to contribute to more seamless financial consolidation, regulatory compliance, and consistent reporting . Management also noted that the International segment's revenue in the reported fourth quarter of 2025 benefited from operational changes accelerating sales, leading to an approximate 2.5% to 3.5% increase in sales , a trend not expected to recur at the end of fiscal year 2026 . The strategic priorities for the period ahead include leading through innovation across a diverse portfolio, delivering an exceptional customer experience, powering the business through digital solutions and data insights, supporting a workplace where colleagues can thrive, advancing sustainability in animal health for a better future, and performing with excellence and agility.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business Overview — Operating Segments
  2. [2] Item 1, Business Overview — Operating Segments
  3. [3] Item 1, Business Overview — Operating Segments
  4. [4] Item 1, Business Overview — Operating Segments
  5. [5] Item 1, Business Overview — Operating Segments
  6. [6] Item 1, Business Overview — Operating Segments
  7. [7] Item 1, Business Overview — Operating Segments
  8. [8] Item 1, Business Overview — Operating Segments
  9. [9] Item 1, Business Overview — Operating Segments
  10. [10] Item 1, Business Overview — Operating Segments
  11. [11] Item 1, Business Overview — Operating Segments
  12. [12] Item 1, Business Overview — Operating Segments
  13. [13] Item 1, Business Overview — Operating Segments
  14. [14] Item 1, Business Overview — Operating Segments
  15. [15] Item 1, Business Overview — Operating Segments
  16. [16] Item 1, Business Overview — International Operations
  17. [17] Item 1, Business Overview — Sales and Marketing
  18. [18] Item 1, Business Overview — Customers
  19. [19] Item 1, Business Overview — Research and Development
  20. [20] Item 1, Business Overview — Manufacturing and Supply Chain
  21. [21] Item 1, Business Overview — Competition
  22. [22] Item 1, Business Overview — Intellectual Property
  23. [23] Item 1, Business Overview — Regulatory
  24. [24] Item 1, Business Overview — Human Capital Management
  25. [25] Item 1, Business Overview — Environmental, Health and Safety
  26. [26] Item 7, MD&A — Overview of our business
  27. [27] Item 7, MD&A — Overview of our business
  28. [28] Item 7, MD&A — Overview of our business
  29. [29] Item 7, MD&A — Overview of our business
  30. [30] Item 1, Business Overview — Products
  31. [31] Item 1, Business Overview — Products
  32. [32] Item 1, Business Overview — Products
  33. [33] Item 1, Business Overview — Products
  34. [34] Item 1, Business Overview — Products
  35. [35] Item 4, Revenue — Revenue by product category
  36. [36] Item 4, Revenue — Revenue by product category
  37. [37] Item 4, Revenue — Revenue by product category
  38. [38] Item 4, Revenue — Revenue by product category
  39. [39] Item 4, Revenue — Revenue by product category
  40. [40] Item 4, Revenue — Revenue by product category
  41. [41] Item 4, Revenue — Revenue by product category
  42. [42] Item 4, Revenue — Revenue by product category
  43. [43] Item 1, Business Overview — Products
  44. [44] Item 1, Business Overview — Products
  45. [45] Item 1, Business Overview — Products
  46. [46] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  47. [47] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  48. [48] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  49. [49] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  50. [50] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  51. [51] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  52. [52] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  53. [53] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  54. [54] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  55. [55] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  56. [56] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  57. [57] Item 7, MD&A — Analysis of the Consolidated Statements of Income
  58. [58] Item 8, Consolidated Statements of Income
  59. [59] Item 8, Consolidated Statements of Income
  60. [60] Item 8, Consolidated Statements of Cash Flows
  61. [61] Item 8, Consolidated Balance Sheets
  62. [62] Item 8, Consolidated Balance Sheets
  63. [63] Item 7, MD&A — Revenue
  64. [64] Item 7, MD&A — Revenue
  65. [65] Item 7, MD&A — Revenue
  66. [66] Item 7, MD&A — Revenue
  67. [67] Item 7, MD&A — Revenue
  68. [68] Item 7, MD&A — Revenue
  69. [69] Item 7, MD&A — Revenue
  70. [70] Item 7, MD&A — Revenue
  71. [71] Item 7, MD&A — Revenue
  72. [72] Item 7, MD&A — Revenue
  73. [73] Item 7, MD&A — Operating Segment Results
  74. [74] Item 7, MD&A — Operating Segment Results
  75. [75] Item 7, MD&A — Operating Segment Results
  76. [76] Item 7, MD&A — Operating Segment Results
  77. [77] Item 7, MD&A — Operating Segment Results
  78. [78] Item 7, MD&A — Operating Segment Results
  79. [79] Item 7, MD&A — Operating Segment Results
  80. [80] Item 7, MD&A — Operating Segment Results
  81. [81] Item 7, MD&A — Operating Segment Results
  82. [82] Item 1, Business Overview — Products
  83. [83] Item 1, Business Overview — Products
  84. [84] Item 1, Business Overview — Products
  85. [85] Item 1, Business Overview — Products
  86. [86] Item 1, Business Overview — Products
  87. [87] Item 1, Business Overview — Products
  88. [88] Item 1, Business Overview — Products
  89. [89] Item 1, Business Overview — Products
  90. [90] Item 1, Business Overview — Products
  91. [91] Item 1, Business Overview — Products
  92. [92] Item 1, Business Overview — Products
  93. [93] Item 1, Business Overview — Products
  94. [94] Item 1, Business Overview — Products
  95. [95] Item 1, Business Overview — Products
  96. [96] Item 1, Business Overview — Products
  97. [97] Item 1, Business Overview — Products
  98. [98] Item 1, Business Overview — Products
  99. [99] Item 1, Business Overview — Products
  100. [100] Item 1, Business Overview — Products
  101. [101] Item 7, MD&A — Fiscal Year Alignment of International Subsidiaries
  102. [102] Item 7, MD&A — Fiscal Year Alignment of International Subsidiaries
  103. [103] Item 7, MD&A — Fiscal Year Alignment of International Subsidiaries
  104. [104] Item 7, MD&A — Fiscal Year Alignment of International Subsidiaries
  105. [105] Item 7, MD&A — Our strategic pillars
  106. [106] Item 7, MD&A — Product development initiatives
  107. [107] Item 1, Business Overview — Research and Development
  108. [108] Item 1, Business Overview — Research and Development
  109. [109] Item 1, Business Overview — Manufacturing and Supply Chain
  110. [110] Item 1, Business Overview — Manufacturing and Supply Chain
  111. [111] Item 7, MD&A — Certain significant items
  112. [112] Item 1, Business Overview — Research and Development
  113. [113] Item 1, Business Overview — Research and Development
  114. [114] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  115. [115] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  116. [116] Item 8, Consolidated Statements of Income
  117. [117] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  118. [118] Item 7, MD&A — Pension obligations
  119. [119] Item 1A, Risk Factors — The animal health industry is highly competitive.
  120. [120] Item 1A, Risk Factors — The animal health industry is highly competitive.
  121. [121] Item 1A, Risk Factors — The animal health industry is highly competitive.
  122. [122] Item 7, MD&A — Competition
  123. [123] Item 7, MD&A — Competition
  124. [124] Item 1A, Risk Factors — Consolidation of our customers and distributors could negatively affect the pricing of our products.
  125. [125] Item 1A, Risk Factors — Changes in distribution channels for companion animal products could negatively impact our market share, margins and distribution of our products.
  126. [126] Item 1A, Risk Factors — A significant portion of our operations are conducted in foreign jurisdictions, including jurisdictions presenting a high risk of bribery and corruption, and are subject to the economic, political, legal and business environments of the countries in which we do business.
  127. [127] Item 1A, Risk Factors — Our business is subject to risk based on global economic and political conditions.
  128. [128] Item 7, MD&A — Perceptions of product quality, safety and reliability
  129. [129] Item 7, MD&A — Perceptions of product quality, safety and reliability
  130. [130] Item 1A, Risk Factors — Increased regulation or decreased governmental financial support relating to the raising, processing or consumption of food-producing animals could reduce demand for our livestock products.
  131. [131] Item 1A, Risk Factors — Changes in trade policies, including the imposition of tariffs, sanctions, and other trade restrictions, may adversely affect our business.
  132. [132] Item 1A, Risk Factors — Our business may be negatively affected by weather conditions, natural disasters and the availability of natural resources.

Analysis on 5/19/2026